Drug safety sciences and the bottleneck in drug development
During a recent review of a new drug application for treatment of a chronic disease, US Food and Drug Administration (FDA) regulators agreed with the sponsor's assessment of efficacy. However, it was noted that two subjects receiving active treatment experienced abnormal liver chemistries that...
Uloženo v:
| Vydáno v: | Clinical pharmacology and therapeutics Ročník 89; číslo 6; s. 788 |
|---|---|
| Hlavní autor: | |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
01.06.2011
|
| Témata: | |
| ISSN: | 1532-6535, 1532-6535 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | During a recent review of a new drug application for treatment of a chronic disease, US Food and Drug Administration (FDA) regulators agreed with the sponsor's assessment of efficacy. However, it was noted that two subjects receiving active treatment experienced abnormal liver chemistries that possibly, but not definitely, indicated a liver safety liability. The sponsor was told that a prerequisite for approval would be a new clinical trial involving 20,000 patients treated for 1 year, with 10,000 receiving the new drug and 10,000 receiving a comparator treatment. The sponsor is now faced with the substantial costs involved in undertaking such a large study, the loss of patent life during the conduct and analysis of the study, and the prospect of losing in-class market position. If the drug is ultimately approved, this detour will result in costs and potential revenue loss to the sponsor of well over $1 billion. |
|---|---|
| AbstractList | During a recent review of a new drug application for treatment of a chronic disease, US Food and Drug Administration (FDA) regulators agreed with the sponsor's assessment of efficacy. However, it was noted that two subjects receiving active treatment experienced abnormal liver chemistries that possibly, but not definitely, indicated a liver safety liability. The sponsor was told that a prerequisite for approval would be a new clinical trial involving 20,000 patients treated for 1 year, with 10,000 receiving the new drug and 10,000 receiving a comparator treatment. The sponsor is now faced with the substantial costs involved in undertaking such a large study, the loss of patent life during the conduct and analysis of the study, and the prospect of losing in-class market position. If the drug is ultimately approved, this detour will result in costs and potential revenue loss to the sponsor of well over $1 billion. During a recent review of a new drug application for treatment of a chronic disease, US Food and Drug Administration (FDA) regulators agreed with the sponsor's assessment of efficacy. However, it was noted that two subjects receiving active treatment experienced abnormal liver chemistries that possibly, but not definitely, indicated a liver safety liability. The sponsor was told that a prerequisite for approval would be a new clinical trial involving 20,000 patients treated for 1 year, with 10,000 receiving the new drug and 10,000 receiving a comparator treatment. The sponsor is now faced with the substantial costs involved in undertaking such a large study, the loss of patent life during the conduct and analysis of the study, and the prospect of losing in-class market position. If the drug is ultimately approved, this detour will result in costs and potential revenue loss to the sponsor of well over $1 billion.During a recent review of a new drug application for treatment of a chronic disease, US Food and Drug Administration (FDA) regulators agreed with the sponsor's assessment of efficacy. However, it was noted that two subjects receiving active treatment experienced abnormal liver chemistries that possibly, but not definitely, indicated a liver safety liability. The sponsor was told that a prerequisite for approval would be a new clinical trial involving 20,000 patients treated for 1 year, with 10,000 receiving the new drug and 10,000 receiving a comparator treatment. The sponsor is now faced with the substantial costs involved in undertaking such a large study, the loss of patent life during the conduct and analysis of the study, and the prospect of losing in-class market position. If the drug is ultimately approved, this detour will result in costs and potential revenue loss to the sponsor of well over $1 billion. |
| Author | Watkins, P B |
| Author_xml | – sequence: 1 givenname: P B surname: Watkins fullname: Watkins, P B email: pbwatkins@med.unc.edu organization: Hamner-University of North Carolina, Institute for Drug Safety Sciences, Schools of Medicine and Pharmacy, University of North Carolina, Chapel Hill, North Carolina, USA. pbwatkins@med.unc.edu |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/21593756$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNz8tLxDAYBPAgK-5Db54lN09d826CJ1mfsOBl7yVNvmo1TWuTCvvfq7iCp5nDj4FZolnsIyB0TsmaEq6vXBjymhFK14ofoQWVnBVKcjn71-domdIbIUQYrU_QnFFpeCnVAl3fjtMLTraBvMfJtRAdJGyjx_kVcN3nHCCCe8dtxP6HeviE0A8dxHyKjhsbEpwdcoV293e7zWOxfX542txsC8e55oWVnghbN0J4YoQhHGhjlRRK1ro2ntmyLJUxgnPfSMEMaEc0qZWQxilt2Qpd_s4OY_8xQcpV1yYHIdgI_ZQqrTThxFD2LS8Ocqo78NUwtp0d99XfXfYFJehXMw |
| CitedBy_id | crossref_primary_10_1124_dmd_118_082834 crossref_primary_10_3390_ijms24054459 crossref_primary_10_1038_nrd3801 crossref_primary_10_1517_17460441_2011_625652 crossref_primary_10_2147_DDDT_S523455 crossref_primary_10_1038_labinvest_2017_22 crossref_primary_10_1124_jpet_118_255026 crossref_primary_10_1053_j_gastro_2013_12_032 crossref_primary_10_1016_j_cbi_2015_11_008 crossref_primary_10_1016_j_ygeno_2022_110330 crossref_primary_10_1007_s40264_014_0181_8 crossref_primary_10_1007_s00204_017_2002_1 crossref_primary_10_1007_s00204_020_02763_w crossref_primary_10_1038_s41746_024_01349_5 crossref_primary_10_1039_C9RA03225H crossref_primary_10_1002_term_1652 crossref_primary_10_1517_14740338_2016_1160057 crossref_primary_10_1016_j_biopha_2024_117422 crossref_primary_10_1016_j_toxlet_2015_04_014 crossref_primary_10_1007_s43188_025_00289_w crossref_primary_10_1080_03602532_2025_2472076 crossref_primary_10_1007_s40203_022_00135_z crossref_primary_10_1016_j_csbr_2024_100011 crossref_primary_10_1016_j_tox_2025_154234 crossref_primary_10_1038_s41598_022_05697_8 crossref_primary_10_1016_j_bios_2022_114617 crossref_primary_10_3390_molecules28217417 crossref_primary_10_1111_cas_16131 crossref_primary_10_1109_JBHI_2024_3350083 crossref_primary_10_1177_01926233241303890 crossref_primary_10_1111_cts_12629 crossref_primary_10_3389_fphar_2021_680618 crossref_primary_10_2174_1875318301909010055 crossref_primary_10_1016_j_toxlet_2014_02_007 crossref_primary_10_1080_00498254_2018_1453100 crossref_primary_10_1002_bdd_1878 crossref_primary_10_1002_j_2055_2335_2011_tb00671_x crossref_primary_10_1016_j_tiv_2020_105010 crossref_primary_10_1177_01926233241230543 crossref_primary_10_1093_toxsci_kfab116 crossref_primary_10_1002_jat_4144 crossref_primary_10_1016_j_dmpk_2023_100511 crossref_primary_10_1016_j_taap_2024_117064 crossref_primary_10_1124_dmd_124_001675 crossref_primary_10_1016_j_reprotox_2022_05_005 crossref_primary_10_1124_jpet_112_194167 crossref_primary_10_1002_hep_26414 crossref_primary_10_1016_j_tiv_2015_03_005 crossref_primary_10_1016_j_biomaterials_2020_120529 crossref_primary_10_1002_jat_4538 crossref_primary_10_3389_fgene_2022_867946 crossref_primary_10_1093_bib_bbaf347 crossref_primary_10_1016_j_apsb_2021_11_013 crossref_primary_10_1016_j_tiv_2015_01_003 crossref_primary_10_1016_j_jep_2025_120315 crossref_primary_10_1016_j_tox_2024_153829 crossref_primary_10_1007_s10620_021_07223_8 crossref_primary_10_1016_j_jceh_2012_05_002 crossref_primary_10_1007_s00204_025_04089_x crossref_primary_10_1016_j_tiv_2016_02_019 crossref_primary_10_1002_jat_2864 crossref_primary_10_1517_14740338_2013_770470 crossref_primary_10_1016_j_fct_2024_114631 crossref_primary_10_1016_j_toxlet_2018_06_1069 crossref_primary_10_1007_s44164_025_00089_4 crossref_primary_10_1016_j_fct_2017_10_026 crossref_primary_10_1289_EHP11891 crossref_primary_10_2217_bmm_13_42 crossref_primary_10_1186_1471_2105_14_S14_S11 crossref_primary_10_2174_1574893615666191219094216 crossref_primary_10_1016_j_tiv_2017_09_012 crossref_primary_10_1177_1535370217740853 crossref_primary_10_1016_j_bcp_2025_116869 crossref_primary_10_1093_toxsci_kft189 crossref_primary_10_1016_j_drudis_2019_09_022 crossref_primary_10_1080_03602532_2021_1894571 crossref_primary_10_1038_s41598_023_40004_z crossref_primary_10_3390_metabo15040240 crossref_primary_10_1155_2017_9658018 crossref_primary_10_1111_liv_70287 crossref_primary_10_3389_fphar_2023_1239395 crossref_primary_10_1002_pds_5161 crossref_primary_10_1080_17474124_2016_1196133 crossref_primary_10_1093_toxsci_kfae123 crossref_primary_10_1371_journal_pone_0197213 crossref_primary_10_1016_j_tiv_2017_05_001 crossref_primary_10_1002_adma_201602448 crossref_primary_10_1080_17460441_2021_1931114 crossref_primary_10_1111_1751_2980_12684 crossref_primary_10_1097_HEP_0000000000001007 crossref_primary_10_1124_pharmrev_120_000238 crossref_primary_10_21443_1560_9278_2025_28_2_143_150 crossref_primary_10_1002_jat_2960 crossref_primary_10_1038_clpt_2013_182 crossref_primary_10_1002_psp4_12303 crossref_primary_10_1038_s41598_021_85708_2 crossref_primary_10_3390_molecules25030481 crossref_primary_10_1002_cpt_564 crossref_primary_10_1038_s41467_024_55571_6 crossref_primary_10_1038_clpt_2013_29 crossref_primary_10_1080_14740338_2021_1867104 crossref_primary_10_1016_j_omtm_2023_08_003 crossref_primary_10_3390_pharmaceutics16070928 crossref_primary_10_1016_j_cbi_2024_111133 crossref_primary_10_1038_s41598_020_61872_9 crossref_primary_10_3390_cells13181542 crossref_primary_10_1007_s00204_021_03141_w crossref_primary_10_1016_j_jhep_2023_01_019 crossref_primary_10_1016_j_cbi_2018_09_011 crossref_primary_10_1186_2050_6511_15_42 crossref_primary_10_1002_cpt_711 crossref_primary_10_1002_bit_28010 crossref_primary_10_1007_s00204_020_02804_4 crossref_primary_10_1080_01480545_2023_2178451 crossref_primary_10_1016_j_taap_2023_116675 crossref_primary_10_1016_j_tiv_2014_03_006 crossref_primary_10_3390_molecules23102486 crossref_primary_10_3390_pharmaceutics15010055 crossref_primary_10_1007_s11096_025_01935_x crossref_primary_10_1038_s41598_022_09309_3 crossref_primary_10_2217_pgs_12_45 crossref_primary_10_1016_j_jhep_2015_04_016 crossref_primary_10_1007_s43188_025_00310_2 crossref_primary_10_1007_s40290_013_0015_5 crossref_primary_10_1371_journal_pone_0257477 crossref_primary_10_1039_C3TX50077B crossref_primary_10_1208_s12248_018_0204_y |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1038/clpt.2011.63 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1532-6535 |
| ExternalDocumentID | 21593756 |
| Genre | Journal Article Review |
| GeographicLocations | United States |
| GeographicLocations_xml | – name: United States |
| GroupedDBID | --- --K -Q- .55 .GJ 0R~ 1B1 1CY 1OB 1OC 29B 33P 354 36B 39C 3O- 4.4 52O 53G 5GY 5RE 6J9 70F 8F7 AAESR AAHQN AAIPD AAKAS AAMMB AAMNL AANHP AANLZ AAONW AAQOH AAQQT AAWTL AAYCA AAZKR ABCUV ABJNI ABLJU ABQWH ACBNA ACBWZ ACCZN ACGFO ACGFS ACGOF ACPOU ACRPL ACXQS ACYXJ ADBBV ADBTR ADKYN ADNMO ADXAS ADZCM ADZMN AEFGJ AEGXH AEIGN AENEX AEUYR AEYWJ AFBPY AFFNX AFFPM AGHNM AGQPQ AGXDD AGYGG AHBTC AI. AIAGR AIDQK AIDYY AITYG AIURR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMYDB ASPBG AVWKF AZFZN AZVAB BDRZF BFHJK BMXJE BRXPI C45 CAG CGR COF CS3 CUY CVF DCZOG DPXWK DU5 EBS ECM EE. EIF EJD EMOBN F5P GODZA GWYGA HGLYW IH2 IHE J5H L7B LATKE LEEKS LITHE LOXES LSO LUTES LYRES M41 MEWTI N4W N9A NPM NQ- O9- OPC OVD P2P P2W PALCI RIG RIWAO RJQFR RNTTT ROL RPZ SAMSI SEW SJN SUPJJ TEORI TWZ UHS VH1 WBKPD WH7 WOHZO WXSBR X7M Y6R YFH YOC YXB ZGI ZXP ZZTAW 7X8 |
| ID | FETCH-LOGICAL-c3383-a5d04abf44d094903e1fa65465b8b9d2a777699433df5429e8c080b6459c68a2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 156 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000290786000014&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1532-6535 |
| IngestDate | Sun Nov 09 11:47:43 EST 2025 Mon Jul 21 05:56:57 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c3383-a5d04abf44d094903e1fa65465b8b9d2a777699433df5429e8c080b6459c68a2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| PMID | 21593756 |
| PQID | 868030912 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_868030912 pubmed_primary_21593756 |
| PublicationCentury | 2000 |
| PublicationDate | 2011-Jun 20110601 |
| PublicationDateYYYYMMDD | 2011-06-01 |
| PublicationDate_xml | – month: 06 year: 2011 text: 2011-Jun |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Clinical pharmacology and therapeutics |
| PublicationTitleAlternate | Clin Pharmacol Ther |
| PublicationYear | 2011 |
| SSID | ssj0004988 |
| Score | 2.4230409 |
| SecondaryResourceType | review_article |
| Snippet | During a recent review of a new drug application for treatment of a chronic disease, US Food and Drug Administration (FDA) regulators agreed with the sponsor's... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 788 |
| SubjectTerms | Animals Clinical Trials as Topic - economics Clinical Trials as Topic - methods Drug Approval - economics Drug Approval - methods Drug Discovery - economics Drug Discovery - methods Drug Discovery - standards Drug-Related Side Effects and Adverse Reactions - economics Drug-Related Side Effects and Adverse Reactions - prevention & control Humans United States |
| Title | Drug safety sciences and the bottleneck in drug development |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/21593756 https://www.proquest.com/docview/868030912 |
| Volume | 89 |
| WOSCitedRecordID | wos000290786000014&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV27TsMwFLWAMrDwfpSXPKBOtdrYThyLASGgYqHK0KFb5SeqQGlpWqT-PddJSlkQAxkyJVJ0c-1zfH19DkI31FBNpWEkFt4T7qkhEnCXABhGXDjpYs1LswnR76fDoczq3pyibqtczYnlRG0nJtTIO2mSht2AiN5NP0gwjQqbq7WDxiZqMGAyoaNLDH-IhcvSdhLGNCVJzOK6773L0o55n84r_c6g__kbtywxprf3z6_bR7s1ucT3VTYcoA2XH6JWVqlTL9t4sD5sVbRxC2dr3erlEbp9nC1ecaG8my9xjYwFVrnFQBJxsBwDhHLmDY9zbMOjdt1wdIwGvafBwzOpvRWICYtSomLb5Up7zi0s8GSXucir0hldp1paqoQQiZScMeuDpZVLgyS5DtIzJkkVPUFb-SR3ZwhH0qdUaYB5prngUjO44BcnXgE3SWwT4VXIRpC6YT9C5W6yKEbfQWui0yrso2klsTECIgK8KU7O_375Au1Udd5QGblEDQ_D1l2hbfM5Hxez6zIl4N7PXr4AtHW_3w |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Drug+safety+sciences+and+the+bottleneck+in+drug+development&rft.jtitle=Clinical+pharmacology+and+therapeutics&rft.au=Watkins%2C+P+B&rft.date=2011-06-01&rft.issn=1532-6535&rft.eissn=1532-6535&rft.volume=89&rft.issue=6&rft.spage=788&rft_id=info:doi/10.1038%2Fclpt.2011.63&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1532-6535&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1532-6535&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1532-6535&client=summon |